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Abstract
Background Intrahepatic cholangiocarcinoma (IHCC) is a highly malignant neoplasm, but the prognostic factors of IHCC
are not yet fully understood. The matrix metalloproteinases (MMPs) are known to be related to tumor viability. The aim of
this study was to evaluate the prognostic significance of clinicopathological and immunohistochemical characteristics of
resected IHCC.
Patients and Methods From 1996 to 2006, we surgically treated 35 patients with IHCC. Clinicopathological and immuno-
histochemical characteristics, including expression of MMPs, vascular endothelial growth factor, and epidermal growth
factor receptor in the resected specimens, were investigated, and overall survival rates were evaluated with regard to the
characteristics using univariate and multivariate analyses.
Results Univariate analysis revealed the significant prognostic factors to be preoperative serum CEA and CA19-9, intra-
operative transfusion, tumor size, surgical margin, lymph node metastasis, invasion of portal and hepatic vein, intrahepatic
metastasis, UICC stage, and expression of MMP-7. Subsequent multivariate analysis indicated that MMP-7 was an
independent prognostic factor (hazard ratio (HR), 4.698; 95% confidence interval (CI), 0.057–0.866; P00.03) along with
intrahepatic metastasis (HR, 5.694; 95% CI, 0.029–0.706; P00.017).
Conclusion MMP-7 expression is associated with a poor prognosis in patients with resected IHCC.
Keywords Cholangiocarcinoma.Matrixmetalloprotease.
Matrix metalloprotease-7.Prognosticfactor
Introduction
Intrahepatic cholangiocarcinoma (IHCC) is a highly malig-
nant neoplasm originating from the bile duct system with
markers of cholangiocyte differentiation.
1,2 The incidence of
IHCC is increasing worldwide, and it is the second most
common form of primary liver cancer next to that of hepa-
tocellular carcinoma. Despite advances in diagnosis and
treatment, most patients present with advanced metastatic
lesions and are not amenable to surgical extirpation or liver
transplantation.
3–7 Furthermore, the current chemotherapy
regimen that is used to treat IHCC offers very limited benefit
in terms of patient survival. When compared with other
malignancies, IHCC is generally characterized by strong
proliferation, invasion, and early metastasis.
Matrix metalloproteinases (MMPs) are zinc-dependent
neutral endopeptidases, which participate in degradation of
extracellularmatrixproteins.
8,9Theyplayroles in manyphys-
iological processes, such as bone remodeling and organogen-
esis, and have additional roles in the reorganization of tissues
during pathological conditions such as inflammation, inva-
sion, and metastasis of cancer cells.
8,10 Many recent studies
haveprovidedevidencethatthebiologicalactivitiesofvarious
cell surface molecules are proteolytically modulated by sev-
eral MMPs, including MMP-2, -9, and -7.
11–13 These MMPs
are likely to regulate cellular functions by activating, inacti-
vating, or releasing membrane proteins. Such regulation of
cell surface proteins, as well as MMP-catalyzed degradation
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tumor invasion,isimportant totumor invasionand metastasis.
MMP-7, the smallest of the MMPs, has broad substrate
specificity and has been demonstrated to degrade or process a
variety of matrix and non-matrix molecules.
14 Unlike most
MMPs, which are expressed by stromal cells, MMP-7 is prin-
cipally expressed by epithelial cells.
15 In human cholangiocar-
cinomas, this enzyme appears to be one of the most important
MMPs because the expression of MMP-7 correlates highly
with the malignant and metastatic potentials of the cancers.
16
In this study, we investigated the association of clinico-
pathological characteristics of resected IHCCs with progno-
sis. To improve the prognosis in IHCC, we believe that a
fuller, more detailed understanding of the prognostic factors
of IHCC is required.
Patients and Methods
Patients
From 1996 to 2006, a total of 35 Japanese patients with
IHCC underwent hepatectomies at the Department of Sur-
gery I, Oita University Faculty of Medicine, Oita, Japan
(Table 1). IHCC was defined as a malignancy arising from
the intrahepatic bile duct; perihilar tumors were excluded.
Patient age was 65±10 years (mean±SD), and the patients
included 9 women and 26 men with a female-to-male ratio
of 1:2.9. All patients underwent surgery in our institution.
The surgical methods used were right trisectionectomy (n0
1), right hepatectomy including extended right hepatectomy
(n012), left hepatectomy including extended left hepatecto-
my (n018), and others (n04). Clinical characteristics and
histopathological and immunohistochemical findings of the
IHCC patients were examined retrospectively. We followed
the guidelines of the ethical principles of the World Medical
Association’s Declaration of Helsinki in this study.
Histopathological Assessment
Tumor staging and histological classification were assessed
according to the TNM Classification of Malignant Tumours
defined by the International Union Against cancer. Accord-
ing to the General Rules for the Clinical and Pathological
Study of Primary Liver Cancer,
17 macroscopic types of
IHCC were classified into two groups: the mass-forming
type and other types, which include the periductal and the
intraductal growth types. Data for other clinicopathological
factors including age, sex, preoperative serum levels of
carcinoembryonic antigen (CEA) and CA19-9, operation
time, blood loss, transfusion, tumor size, differentiation,
lymph node metastasis, invasion of portal and hepatic vein,
bile duct invasion, surgical margin, intrahepatic metastasis,
and UICC stage were categorized as shown in Table 2.
Immunohistochemistry
Immunohistochemistry for MMP-2, -7, -9, vascular endo-
thelial growth factor (VEGF), and epidermal growth factor
receptor (EGFR) was performed using an Envision+system
(Dako, Cytomation, Glostrup, Denmark). Sources and dilu-
tions of primary antibodies were as follows: anti MMP-2, -7,
-9 (mouse monoclonal; diluted 1:100; Daiichi Fine Chemi-
cal Co., Ltd., Toyama, Japan), anti-VEGF (mouse monoclo-
nal; diluted 1:100; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), and anti-EGFR (mouse monoclonal, diluted
1:500; Santa Cruz Biotechnology, Inc.).
Formalin-fixed, paraffin-embedded serial tissue sections
(4 μm) were deparaffinized and rehydrated in xylene and
grade-diluted ethanol (50–100%) and submerged for 20 min
in 0.3% H2O2 with absolute methanol to block endogenous
peroxidase activity. After protein blocking, the sections
were incubated with each primary antibody at room temper-
ature for 2 h. The sections were then treated for 20 min with
biotinylated anti-mouse IgG (Nichirei Biosciences Inc.,
Tokyo, Japan), followed by treatment for 30 min with strep-
tavidin–biotin–peroxidase complex (Nichirei Biosciences
Inc.), at room temperature with a PBS wash between each
step. The slides were developed with diaminobenzidine-
H2O2 (DAB+system, Dako Japan Inc., Tokyo, Japan). The
nuclei were also lightly stained with hematoxylin.
Evaluation of Immunohistochemistry
The slides were reviewed by two independent observers
who had no knowledge of patient outcomes. The expression
of MMPs was evaluated semiquantitatively according to the
percentage of positively stained cells: negative (positive
Table 1 Patient characteristics
Number of patients 35
Age (years) 64.9±10.3
Sex (male/female) 26/9
Operative procedure
Right trisectionectomy 1
Right hepatectomy 12
Left hepatectomy 18
Others 4
Operation time (min) 463±170
Blood loss (g) 1,190±750
Transfusion 17 (48.6%)
Tumor size (mm) 58.9±31.2
Surgical margin (mm) 5.6±7.1
Complications 16 (45.7%)
Postoperative hospital stay (days) 40.2±21.6
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tumor cells/total tumor cells >10%). The expression of
MMPs in the stromal and inflammatory cells was not eval-
uated in this study. The expression of VEGF was defined as
follows: negative (positive tumor cells/total tumor cells
≤30%) and positive (positive tumor cells/total tumor cells
>30%). The expression of EGFR was defined as follows:
negative (positive tumor cells/total tumor cells ≤10%) and
positive (positive tumor cells/total tumor cells >10%).
Statistical Analysis
Results are expressed as means±SD. Postoperative survival
probabilities were calculated by the Kaplan–Meier method
and analyzed by the log-rank test. Difference was regarded
as significant when the P value was less than 0.05. Multi-
variate analyses were performed using the factors identified
as significant by univariate analyses. All statistical analyses
were performed using Dr SPSS II software (version 11.01 J;
SPSS Japan Inc., Tokyo, Japan).
Results
Overall Survival and Results of Univariate Analysis
Overall 2- and 5-year survival rates were 50.1% and 43.3%,
respectively (Fig. 1). Results of the univariate analysis
Table 2 Results of univariate analysis
Factors Population P value
Age 0.9342
<65 years old 16 (45.7%)
≥65 years old 19 (54.3%)
Sex 0.2666
Male 26 (74.3%)
Female 9 (25.7%)
CEA 0.0005
<5 ng/mL 27 (77.1%)
≥5 ng/mL 8 (22.9%)
CA19-9 0.0002
<100 U/mL 21 (60%)
≥100 U/mL 14 (40%)
Operative procedure 0.8683
<Right hepatectomy 22 (64.7%)
≥Right hepatectomy 13 (35.3%)
Operation time 0.0756
<400 min 16 (45.7%)
≥400 min 19 (54.3%)
Blood loss 0.2382
<1,000 g 18 (51.4%)
≥1,000 g 17 (48.6%)
Transfusion 0.0259
Yes 17 (48.6%)
No 18 (51.4%)
Tumor size (mm) 0.0034
<50 mm 17 (48.6%)
≥50 mm 18 (51.4%)
Surgical margin 0.0057
Negative 31 (88.6%)
Positive 4 (11.4%)
Complications 0.7916
Yes 16 (45.7%)
No 19 (54.3%)
Macroscopic type 0.6720
Mass forming 28 (80%)
Non-mass forming 7 (20%)
Differentiation 0.3813
Well to moderate 22 (62.9%)
Poor 13 (37.1%)
Lymph node metastasis 0.0001
Negative 25 (71.4%)
Positive 10 (28.6%)
Invasion of portal vein 0.0072
Negative 20 (57.1%)
Positive 15 (42.9%)
Invasion of hepatic vein 0.0067
Negative 25 (71.4%)
Positive 10 (28.6%)
Bile duct invasion 0.7648
Negative 15 (45.5%)
Positive 18 (54.6%)
Table 2 (continued)
Factors Population P value
Intrahepatic metastasis 0.0001
Negative 21 (60%)
Positive 14 (40%)
UICC stage 0.0038
Stage I/II 13 (37.1%)
Stage III/IV 22 (62.9%)
MMP-2 0.4572
Negative 23 (65.7%)
Positive 12 (34.3%)
MMP-7 0.0003
Negative 15 (42.9%)
Positive 20 (57.1%)
MMP-9 0.7037
Negative 22 (62.9%)
Positive 13 (37.1%)
VEGF 0.5667
Negative 19 (57.6%)
Positive 14 (42.4%)
EGFR 0.1450
Negative 26 (74.3%)
Positive 9 (25.7%)
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Table 2. The univariate analysis revealed the statistically
significant prognostic factors among the clinicopatholog-
ical characteristics to be preoperative serum levels of
CEA and CA19-9, intraoperative transfusion, tumor size,
surgical margin, lymph node metastasis, invasion of
portal and hepatic veins, intrahepatic metastasis, and
UICC stage.
Immunohistochemical results of expression rates of
MMP-2, -7, -9; VEGF; and EGFR and the univariate anal-
ysis of prognostic factors for overall survival are also listed
in Table 2.M M P - 2 ,- 7 ,- 9 ,V E G F ,a n dE G F Rw e r e
expressed in 23 (65.7%), 15 (42.9%), 22 (62.9%), 19
(57.6%), and 26 (74.3%) of the 35 IHCC patients, respec-
tively. Univariate analysis revealed the statistically signifi-
cant prognostic factor among immunohistochemical
findings to be MMP-7. The 5-year survival rates of MMP-
7(+) and MMP-7(−) patients were 72.7% and 18.3%, re-
spectively (Fig. 2a). Positively stained cancer cells were
distributed heterogeneously in the tumor nests. Carcinoma
cell cytoplasm was stained brown for MMP-7, but stromal
cells (other than some monocytes or surrounding normal
mucosa) were not stained (Fig. 2b, c)
Results of Multivariate Analysis
In this study, 12 factors including MMP-7 expression were
identified as significant prognostic factors by univariate
analysis. Multivariate analysis, using these 12 factors,
revealed that MMP-7 expression was an independent prog-
nostic factor (hazard ratio [HR], 4.698; 95% confidence
interval [CI], 0.057–0.866; P00.03) along with intrahepatic
metastasis (HR, 5.694; 95% CI, 0.029–0.706; P00.017;
Table 3). Lymph node metastasis showed a tendency to
indicate poor prognosis; however, it was not a statistically
significant indicator (HR, 3.426; 95% CI, 0.086–1.073;
P00.064).
Discussion
Many clinicopathological factors, such as lymph node me-
tastasis, UICC stage, surgical margin, R0 resection, cirrho-
sis, use of postoperative adjuvant chemotherapy, and other
factors, are potential prognostic factors after resection of
IHCC.
18–21 However, there has been no definitive way to
predict prognosis of IHCC using molecules. This study was
performed todetermine whether expressionof MMP-2, -7, -9,
VEGF, and EGFR in resected specimens of IHCC can predict
disease outcome. As a result, MMP-7 expression in the tumor
cells was found to be a prognostic factor, in addition to that of
intrahepatic metastasis.
Recently, many targeted therapies against EGFR, VEGF,
and human EGFR type 2 (HER2) such as cetuximab, lapa-
tinib, erlotinib, and bevacizumab have been used for treat-
ment of gastrointestinal cancers. Development of targeted
agents in biliary tract cancer (BTC) including IHCC has
lagged behind other types of tumors, and there are a few
phase II studies examining early experience of efficacy and
safety of targeted therapies for BTC patients.
22–26 Chemo-
therapy has been the main therapeutic modality in locally
advanced or metastatic BTC, and a randomized, controlled,
phase III trial of 410 patients with BTCs has established the
combination of gemcitabine and cisplatin as a new global
standard for the treatment of locally advanced or metastatic
BTC.
27 Although the results are encouraging, the study
strongly suggests that BTC remains very difficult to treat
with current methods, and molecular targeted therapy is
urgently needed for this deadly disease. According to phase
II studies of the targeted therapies, cetuximab may be useful
for BTC when combined with gemcitabine and oxaliplatin.
Gruenberger et al.
22 reported that cetuximab plus gemcita-
bine/oxaliplatin (GEMOX) was well tolerated and had en-
couraging antitumor activity, leading to resection in one
third of patients. These findings warrant further study of
cetuximab plus GEMOX in a large randomized trial. In the
present study, the rate of positivity for EGFR was 74.3%,
and the 5-year survival rates of EGFR(+) and EGFR(−)
patients were 45.9% and 33.3%, respectively. Univariate
analysis revealed that EGFR(+) patients had a tendency for
poor prognosis; however, the difference between EGFR(+)
and EGFR(−) patients was not statistically significant
(P00.145).
MMPs can collectively degrade all components of the
ECM and play important roles in embryo development,
morphogenesis, tissue remodeling, as well as tumor inva-
sion and metastasis.
28,29 With regard to tumor invasion, the
extracellular proteases, especially MMPs, appear to be
43.3%
50.1%
01 0 0 80 60 40 20 (months)
(%)
100
50
0
Fig. 1 Cumulative survival curves in 35 patients with resected IHCC.
Survival rates at 2 and 5 years after operation were 50.1% and 43.3%,
respectively
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into nearby stroma, across blood vessel walls, and through
normal epithelial cell layers has been shown to be promoted
by various MMPs.
28–30 Among the MMPs, MMP-7 is well-
known for its involvement with many malignant tumors.
MMP-7 is associated with malignancies in the colon, pan-
creas, and biliary tract.
31,32 By degrading ECM components
such as type-IV collagen, fibronectin, and laminin, MMP-7
plays important roles in invasion and metastasis of carcino-
ma cells.
33 Interestingly, cleavage of cell surface proteins
other than ECM components by this MMP may also con-
tribute to tumorigenic effects. For example, MMP-7 acti-
vates EGFR by releasing a ligand of epidermal growth
factor and tumor growth factor-α.
34 Moreover, by process-
ing E-cadherin and thereby inducing loose and then tight
aggregation of tumor cells, this proteinase induces homo-
typic adhesion of human colorectal cancer cells and enhan-
ces the metastatic potential in vivo.
35 By disrupting tight
junction structure and a consequent induction of cell
dissociation, MMP-7 might enhance metastasis as well
as invasion of IHCC cells.
36
Some in vitro and in vivo studies have been performed to
determine how MMPs contribute to progression of BTC
including IHCC. It has been reported that the serum level
of MMP-7 is elevated in BTC patients, and this appears to
have a potential to differentiate BTC from benign biliary
tract diseases.
37,38 Moreover, histological expression of
MMP-7 has been reported to be an unfavorable postopera-
tive prognostic factor of BTC.
39,40 Also, higher expression
of MMP-9 is suggested to be associated with the potential of
a
c b
(%)
100
50
0
0 (months) 100 80 60 40 20
MMP-7(-)
MMP-7(+)
Fig. 2 a Cumulative survival
curves in IHCC patients with or
without expression of matrix
metalloproteinase-7 (MMP-7).
The 5-year survival rates of the
patients with and without the
expression of MMP-7 were
72.7% and 18.3%, respectively.
The log-rank test revealed
statistically significant
differences between the two
groups (P00.0003).
Immunostaining for MMP-7 in
tumor tissues: b positive and c
negative staining in cancer
cells. In the positive staining,
cytoplasm of the cancer cells
was stained brown for MMP-7,
but stromal cells were not
stained
Table 3 Results of multivariate analyses regarding overall survival
HR 95% CI P value
CEA 0.001 0.242–4.299 0.978
CA19-9 1.270 0.182–1.583 0.260
Transfusion 1.184 0.211–1.523 0.271
Tumor size (<50, ≥50 mm) 0.364 0.57–1.866 0.546
Surgical margin 1.116 0.45–14.384 0.291
Lymph node metastasis 3.426 0.086–1.073 0.064
Invasion of portal vein 0.422 0.12–2.9 0.516
Invasion of hepatic vein 0.018 0.292–4.103 0.894
Intrahepatic metastasis 5.694 0.029–0.706 0.017
UICC stage 0.006 0.175–6.594 0.938
MMP-7 4.698 0.057–0.866 0.030
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41; however, MMP-9 has not been reported to be a
prognostic factor. With regard to MMP-2, it is controversial
whether this MMP is associated with poor prognosis.
41,42
The multivariate analysis in the present study showed that
immunohistochemical expression of MMP-7 in IHCC tis-
sues was associated with poor prognosis, and expression of
MMP-2 and -9 was not associated with it. This is the first
report, to our knowledge, in which multivariate analysis
shows the clinical significance of MMP-7 expression in
patients with IHCC. In this study, the Kaplan–Meier life
table indicated that 5-year survival was 4 times greater in
patients without MMP-7-expressing tumors compared with
that in patients with MMP-7-expressing tumors (72.7% vs.
18.3%). Therefore, we believe that patients with MMP-7
expressing tumors of IHCC will have poorer prognoses and
should be followed up more closely after the operation. In
addition, MMP-7 could be a potential therapeutic target. If
specific inhibitor of MMP-7 expression by small RNA and
so on is developed in the future,
43 it may be useful to
improve the prognosis in combination with standard
chemotherapy.
In conclusion, the present study suggested that MMP-7 is
associated with a poor prognosis in IHCC patients. However,
this study included a small number of patients, and further
studies enrolling a larger number of patients will be required
to confirm the results of this study.
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